PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:03 AM ET

Sponsor Check › Person

DL
No photo found yet (own website and image search run after this page is viewed)

Daniel Lynch

Named as an officer, director or promoter on SEC Form D filings · MA · May 14, 2009 → Jul 24, 2024

12deals (issuers)
$878.3Mreported sold
259investors
20Form D filings
2009–2024years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 3:01 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Daniel Lynch is listed as an executive officer and director on 20 SEC Form D filings by 12 issuers between May 2009 and Jul 2024. Largest by amount reported sold: Cardurion Pharmaceuticals, Inc. (Burlington, MA — biotechnology — 2024; $260.4M reported sold to 19 investors), 2seventy bio, Inc. (Cambridge, MA — biotechnology — 2022; $170M reported sold to 22 investors), Xilio Therapeutics, Inc. (Waltham, MA — biotechnology — 2021; $95M reported sold to 17 investors), bluebird bio, Inc. (Cambridge, MA — biotechnology — 2012–2021; $75M reported sold to 17 investors), RaNA Therapeutics, LLC (Cambridge, MA — biotechnology — 2015; $63.8M reported sold to 27 investors) and 7 more (all listed below).

What this means That is a lot of deals — 12 separate companies raised money with this person listed as executive officer and director, over about 15 years. Across those companies the filings report $878.3M sold in total.

Listed alongside Amir Nashat (4 shared filings), Nick Leschly (4 shared filings), Wendy L. Dixon (4 shared filings), Jane V. Henderson (3 shared filings), Jean-Francois Formela (3 shared filings) and 111 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Daniel. Each name links to their own page.

The issuers belong to 2 sponsor groups: Bluebird (2 issuers, $245M reported sold, 2010–2022) and Third Rock (7 issuers, $2.62B reported sold, 2010–2026).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 4 bankruptcy cases matching the name listed in Key records below.

What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 20 public filings for Daniel Lynch and found 11 differences, 1 worth asking the sponsor about: Form D filed 303 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Daniel Lynch has not run yet — it is joining a line of 5,337 names; searches run around the clock at the hosts' allowed rate. Searched so far: 27 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 3:01 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Daniel Lynch..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

4 cases: 4 closed (disposition not in docket feed)

Daniel J. Lynch closed
United States Bankruptcy Court, D. Massachusetts · No. 00-42773 · Filed May 17, 2000 · Closed Sep 5, 2000
Role of Daniel J. Lynch: Debtor · Outcome: Case closed 2000-09-05 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 157 federal dockets); 3 people with this name in Form D filings; court in the person's filing state (MA)
Daniel J. Lynch and Kathleen R. Lynch closed
United States Bankruptcy Court, D. Massachusetts · No. 96-44997 · Filed Sep 11, 1996 · Closed Dec 8, 1997
Role of Daniel J. Lynch and Kathleen R. Lynch: Debtor · Outcome: Case closed 1997-12-08 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 157 federal dockets); 3 people with this name in Form D filings; court in the person's filing state (MA)
Daniel J. Lynch closed
United States Bankruptcy Court, D. Massachusetts · No. 95-40646 · Filed Feb 16, 1995 · Closed Jun 22, 1995
Role of Daniel J. Lynch: Debtor · Outcome: Case closed 1995-06-22 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 157 federal dockets); 3 people with this name in Form D filings; court in the person's filing state (MA)
Daniel P. Lynch and Kimberly A. Lynch closed
United States Bankruptcy Court, D. Massachusetts · No. 90-15959 · Filed Oct 15, 1990 · Closed Jun 27, 1991
Role of Daniel P. Lynch and Kimberly A. Lynch: Debtor · Outcome: Case closed 1991-06-27 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 157 federal dockets); 3 people with this name in Form D filings; court in the person's filing state (MA)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 3:01 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

11 differences found between the filings for Daniel Lynch — 1 worth asking about (compared 20 filings on Oct 24, 2026)

Worth asking · Feb 1, 2016 – Nov 30, 2016

Form D filed 303 days after the first sale — PROCLARA BIOSCIENCES, INC.

The filing says the first sale was Feb 1, 2016. The Form D was filed Nov 30, 2016 — 303 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 288 days past that.

What this means The notice went in months after money was taken in. Late notices are common and carry no penalty by themselves, but it is fair to ask the sponsor why the paperwork lagged.

Form D · Nov 30, 2016 ↗PROCLARA BIOSCIENCES, INC. — PartnerFacts page ↗
Sources
Note · Jul 31, 2009 – Jul 6, 2010

Daniel Lynch's role changed at AVILA THERAPEUTICS INC: executive officer, director → director

The Jul 31, 2009 filing lists Daniel Lynch as executive officer, director; the Jul 6, 2010 Form D/A lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Jul 31, 2009 ↗Form D/A · Jul 6, 2010 ↗Daniel Lynch — PartnerFacts page ↗AVILA THERAPEUTICS INC — PartnerFacts page ↗
Sources
Note · May 14, 2009 – Jul 31, 2009

Offering amount changed between filings — AVILA THERAPEUTICS INC

The May 14, 2009 filing says $20,000,000 offered; the Jul 31, 2009 Form D says $30,000,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · May 14, 2009 ↗Form D (later) · Jul 31, 2009 ↗AVILA THERAPEUTICS INC — PartnerFacts page ↗
Sources
Note · Apr 29, 2009 – Nov 30, 2016

6 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — PROCLARA BIOSCIENCES, INC. (latest filing Nov 30, 2016) · No amendment in the last 12 months on an offering that may still be open — RaNA Therapeutics, LLC (latest filing Jul 30, 2015) · No amendment in the last 12 months on an offering that may still be open — Blueprint Medicines Corp (latest filing Jan 17, 2014) · No amendment in the last 12 months on an offering that may still be open — BIND Biosciences, Inc (latest filing Feb 8, 2013) · No amendment in the last 12 months on an offering that may still be open — Stromedix Inc (latest filing Jan 25, 2011) · and 1 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Nov 30, 2016 ↗PROCLARA BIOSCIENCES, INC. — PartnerFacts page ↗Form D · Jul 30, 2015 ↗RaNA Therapeutics, LLC — PartnerFacts page ↗
Sources
Note · May 14, 2009 – Jul 25, 2012

Daniel Lynch is written 2 different ways on the filings

listed as "Daniel Lynch" on 13 filings (from May 14, 2009), and "Daniel S. Lynch" on 7 filings (from Jul 25, 2012).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · May 14, 2009 ↗Form D · Jul 25, 2012 ↗Daniel Lynch — PartnerFacts page ↗
Sources
Note · Mar 17, 2026

Same name, different state: "Daniel Lynch" (IN) is a separate record

This page covers filings where the address state is MA. A separate record, "Daniel Lynch" with address state IN, is listed on 1 filing — most recently by GU Capital LP (Mar 17, 2026). The two records do not overlap in time: this page runs May 14, 2009 to Jul 24, 2024; the other has one filing dated Mar 17, 2026.

What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.

Daniel Lynch (IN) — PartnerFacts page ↗Form D · Mar 17, 2026 ↗GU Capital LP — PartnerFacts page ↗Daniel Lynch (MA) — this page ↗
Sources
Note · Apr 12, 2019

Same name, different state: "Daniel S. Lynch" (MD or CT) is a separate record

This page covers filings where the address state is MA. A separate record, "Daniel S. Lynch" with address state MD or CT, is listed on 2 filings — most recently by SpringWorks Therapeutics, Inc. (Apr 12, 2019). Both records have filings in the same period (Apr 12, 2019).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Daniel S. Lynch (MD,CT) — PartnerFacts page ↗Form D · Apr 12, 2019 ↗SpringWorks Therapeutics, Inc. — PartnerFacts page ↗Daniel Lynch (MA) — this page ↗
Sources
Note · Jan 5, 2017 – May 10, 2019

Address moved from Cambridge, MA to Lexington, MA — Translate Bio, Inc.

The people listed on the Jan 5, 2017 filing give Cambridge, MA; on the May 10, 2019 filing they give Lexington, MA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jan 5, 2017 ↗Form D · May 10, 2019 ↗Translate Bio, Inc. — PartnerFacts page ↗
Sources
Note · May 14, 2009 – Jul 6, 2010

Reported revenue range changed between filings — AVILA THERAPEUTICS INC

"No Revenues" (May 14, 2009); then "Decline to Disclose" (Jul 6, 2010).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · May 14, 2009 ↗Form D/A · Jul 6, 2010 ↗AVILA THERAPEUTICS INC — PartnerFacts page ↗
Sources
Note · Jul 31, 2009 – Jul 6, 2010

Minimum investment changed between filings — AVILA THERAPEUTICS INC

The Jul 31, 2009 filing lists a minimum of $9,531; the Jul 6, 2010 Form D/A lists $0.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Jul 31, 2009 ↗Form D/A (later) · Jul 6, 2010 ↗AVILA THERAPEUTICS INC — PartnerFacts page ↗
Sources
Note · May 14, 2009 – Jul 31, 2009

Minimum investment changed between filings — AVILA THERAPEUTICS INC

The May 14, 2009 filing lists a minimum of $7,206; the Jul 31, 2009 Form D lists $9,531.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · May 14, 2009 ↗Form D (later) · Jul 31, 2009 ↗AVILA THERAPEUTICS INC — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

4 of 18 offerings report sales commissions totalling $8,033,392; 1 reports finder's fees totalling $30,852; 0 report proceeds to related persons.

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jul 24, 2024 D
Cardurion Pharmaceuticals, Inc.
File 021-519629
$0$0$0None listed on this filingEDGAR ↗
Mar 31, 2022 D
2seventy bio, Inc.
File 021-439933
$3,750,000$0$0Goldman Sachs & Co. LLC BrokerCheck CRD 361 ↗EDGAR ↗
Sep 21, 2021 D
bluebird bio, Inc.
File 021-414037
$0$0$0None listed on this filingEDGAR ↗
Feb 26, 2021 D
Xilio Therapeutics, Inc.
File 021-390683
$0$0$0None listed on this filingEDGAR ↗
Jan 21, 2021 D
Xilio Therapeutics, Inc.
File 021-387002
$0$0$0None listed on this filingEDGAR ↗
May 10, 2019 D
Translate Bio, Inc.
File 021-339369
$2,847,299$0$0Jefferies LLC BrokerCheck CRD 2347 ↗
SVB Leerink LLC BrokerCheck CRD 39011 ↗		EDGAR ↗
Apr 5, 2018 D
Eleven Biotherapeutics, Inc.
File 021-309400
$36,093$30,852$0Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗EDGAR ↗
Jan 5, 2017 D
Translate Bio, Inc.
File 021-277689
$0$0$0None listed on this filingEDGAR ↗
Nov 30, 2016 D
PROCLARA BIOSCIENCES, INC.
File 021-275323
$0$0$0None listed on this filingEDGAR ↗
Sep 28, 2016 D
Eleven Biotherapeutics, Inc.
File 021-271427
$0$0$0None listed on this filingEDGAR ↗
Jul 30, 2015 D
RaNA Therapeutics, LLC
File 021-244820
$0$0$0None listed on this filingEDGAR ↗
Dec 5, 2014 D
Eleven Biotherapeutics, Inc.
File 021-229571
$1,400,000$0$0Citigroup Global Markets Inc. BrokerCheck CRD 7059 ↗
Cowen and Company, LLC BrokerCheck CRD 7616 ↗
Leerink Partners LLC BrokerCheck CRD 39011 ↗		EDGAR ↗
Nov 20, 2014 D
Blueprint Medicines Corp
File 021-228724
$0$0$0None listed on this filingEDGAR ↗
Jan 17, 2014 D
Blueprint Medicines Corp
File 021-210375
$0$0$0None listed on this filingEDGAR ↗
Feb 8, 2013 D
BIND Biosciences, Inc
File 021-191591
$0$0$0None listed on this filingEDGAR ↗
Jul 25, 2012 D
bluebird bio, Inc.
File 021-181718
$0$0$0None listed on this filingEDGAR ↗
Jan 25, 2011 D
Stromedix Inc
File 021-154307
$0$0$0None listed on this filingEDGAR ↗
Jul 6, 2010 D/A
AVILA THERAPEUTICS INC
File 021-117636
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 12

Every issuer that named Daniel Lynch on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

CP
Biotechnology

Cardurion Pharmaceuticals, Inc.

Burlington, MA · Jul 24, 2024
  • Jul 24, 2024 · D · $260,410,720 sold of $260,410,720 · 19 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $260.4M from 19 investors (100% of the $260.4M target) as of the latest filing. Daniel is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

2B
Biotechnology · group: Bluebird

2seventy bio, Inc.

Cambridge, MA · Mar 31, 2022
  • Mar 31, 2022 · D · $170,000,009 sold of $170,000,009 · 22 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $170M from 22 investors (100% of the $170M target) as of the latest filing. Daniel is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

BB
Biotechnology · group: Bluebird

bluebird bio, Inc.

Cambridge, MA · Jul 25, 2012 → Sep 21, 2021 · 2 filings
  • Sep 21, 2021 · D · $74,977,264 sold of $74,977,264 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 25, 2012 · D · $60,000,000 sold of $60,000,000 · 17 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $75M from 17 investors (100% of the $75M target) as of the latest filing. Daniel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

XT
Biotechnology

Xilio Therapeutics, Inc.

Waltham, MA · Jan 21, 2021 → Feb 26, 2021 · 2 filings
  • Feb 26, 2021 · D · $94,999,989 sold of $94,999,989 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 21, 2021 · D · $50,249,990 sold of $50,249,990 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $95M from 17 investors (100% of the $95M target) as of the latest filing. Daniel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TB
Biotechnology

Translate Bio, Inc.

Lexington, MA · Jan 5, 2017 → May 10, 2019 · 2 filings
  • May 10, 2019 · D · $47,454,990 sold of $47,454,990 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 5, 2017 · D · $50,999,987 sold of $50,999,987 · 25 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $51M from 25 investors (100% of the $47.5M target) as of the latest filing. Daniel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

EB
Biotechnology

Eleven Biotherapeutics, Inc.

Cambridge, MA · Dec 5, 2014 → Apr 5, 2018 · 3 filings
  • Apr 5, 2018 · D · $996,016 sold of $996,016 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 28, 2016 · D · $13,525,262 sold of $13,525,262 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 5, 2014 · D · $20,000,010 sold of $20,000,010 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20M from 10 investors (100% of the $996K target) as of the latest filing. Daniel is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PB
Biotechnology

PROCLARA BIOSCIENCES, INC.

Cambridge, MA · Nov 30, 2016
  • Nov 30, 2016 · D · $43,035,522 sold of $47,000,003 · 50 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $43M from 54 investors (92% of the $47M target) as of the latest filing. Daniel is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RT
Biotechnology

RaNA Therapeutics, LLC

Cambridge, MA · Jul 30, 2015
  • Jul 30, 2015 · D · $63,812,231 sold of $64,364,708 · 27 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $63.8M from 27 investors (99% of the $64.4M target) as of the latest filing. Daniel is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

BM
Biotechnology · group: Third Rock

Blueprint Medicines Corp

Cambridge, MA · Jan 17, 2014 → Nov 20, 2014 · 2 filings
  • Nov 20, 2014 · D · $50,000,000 sold of $50,000,000 · 29 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 17, 2014 · D · $23,199,996 sold of $25,099,995 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $50M from 29 investors (100% of the $50M target) as of the latest filing. Daniel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

BB
Biotechnology

BIND Biosciences, Inc

Cambridge, MA · Feb 8, 2013
  • Feb 8, 2013 · D · $8,697,684 sold of $20,250,000 · 20 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $25.5M from 21 investors (100% of the $20.3M target) as of the latest filing. Daniel is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

S
Pharmaceuticals

Stromedix Inc

Cambridge, MA · Jan 25, 2011
  • Jan 25, 2011 · D · $2,000,000 sold of $15,500,000 · 9 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $2M from 9 investors (13% of the $15.5M target) as of the latest filing. Daniel is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AT
Biotechnology

AVILA THERAPEUTICS INC

Waltham, MA · May 14, 2009 → Jul 6, 2010 · 3 filings
  • Jul 6, 2010 · D/A · $22,500,000 sold of $30,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 31, 2009 · D · $17,500,000 sold of $30,000,000 · 9 investors · min. $9,531 · role: Executive Officer, Director EDGAR ↗
  • May 14, 2009 · D · $5,000,000 sold of $20,000,000 · 8 investors · min. $7,206 · role: Executive Officer, Director EDGAR ↗

Raised $22.5M from 9 investors (75% of the $30M target) as of the latest filing. Daniel is listed as director, executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (2)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Daniel S. Lynch — MD, CT, 2 issuers, Apr 12, 2019 → Apr 12, 2019 · no shared issuer
  • Daniel Lynch — IN, 1 issuer, Mar 17, 2026 → Mar 17, 2026 · no shared issuer

People around Daniel 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

AN
No photo found yet (own website and image search run after this page is viewed)
Person

Amir Nashat

Director · 4 shared filings (2 issuers) · also on 27 other issuers

Amir Nashat is on 29 issuers in total — a repeat sponsor. Their page lists every one.

NL
No photo found yet (own website and image search run after this page is viewed)
Person

Nick Leschly

Executive Officer, Director · 4 shared filings (3 issuers) · also on 2 other issuers

Nick Leschly is on 5 issuers in total — a repeat sponsor. Their page lists every one.

WD
No photo found yet (own website and image search run after this page is viewed)
Person

Wendy L. Dixon

Director · 4 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

PC
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Chaney

Director · 3 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

RP
No photo found yet (own website and image search run after this page is viewed)
Person

Raj Parekh

Director · 3 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

RL
No photo found yet (own website and image search run after this page is viewed)
Person

Roy R. Lobb

Executive Officer, Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

VS
No photo found yet (own website and image search run after this page is viewed)
Person

Vicki Sato

Director · 3 shared filings (1 issuer) · also on 5 other issuers

Vicki Sato is on 6 issuers in total — a repeat sponsor. Their page lists every one.

JF
No photo found yet (own website and image search run after this page is viewed)
Person

Jean-Francois Formela

Director · 3 shared filings (2 issuers) · also on 24 other issuers

Jean-Francois Formela is on 26 issuers in total — a repeat sponsor. Their page lists every one.

RR
No photo found yet (own website and image search run after this page is viewed)
Person

Ronald C. Renaud Jr.

Executive Officer, Director · 3 shared filings (2 issuers) · also on 4 other issuers

Ronald C. Renaud Jr. is on 6 issuers in total — a repeat sponsor. Their page lists every one.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

Jane V. Henderson

Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

MB
No photo found yet (own website and image search run after this page is viewed)
Person

Michael F. Bigham

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

DG
No photo found yet (own website and image search run after this page is viewed)
Person

David Grayzel

Director · 2 shared filings (1 issuer) · also on 14 other issuers

David Grayzel is on 15 issuers in total — a repeat sponsor. Their page lists every one.

AB
No photo found yet (own website and image search run after this page is viewed)
Person

Alexis Borisy

Executive Officer, Director · 2 shared filings (1 issuer) · also on 15 other issuers

Alexis Borisy is on 16 issuers in total — a repeat sponsor. Their page lists every one.

BG
No photo found yet (own website and image search run after this page is viewed)
Person

Brian Gallagher

Director · 2 shared filings (2 issuers) · also on 5 other issuers

Brian Gallagher is on 7 issuers in total — a repeat sponsor. Their page lists every one.

SK
No photo found yet (own website and image search run after this page is viewed)
Person

STEPHEN KNIGHT

Director · 2 shared filings (1 issuer) · also on 8 other issuers

STEPHEN KNIGHT is on 9 issuers in total — a repeat sponsor. Their page lists every one.

HS
No photo found yet (own website and image search run after this page is viewed)
Person

Henry Skinner

Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

KB
No photo found yet (own website and image search run after this page is viewed)
Person

Katrine Bosley

Executive Officer, Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

BB
No photo found yet (own website and image search run after this page is viewed)
Person

Bruce Booth

Director · 2 shared filings (1 issuer) · also on 20 other issuers

Bruce Booth is on 21 issuers in total — a repeat sponsor. Their page lists every one.

DS
No photo found yet (own website and image search run after this page is viewed)
Person

David Schenkein

Director · 2 shared filings (1 issuer) · also on 4 other issuers

David Schenkein is on 5 issuers in total — a repeat sponsor. Their page lists every one.

CL
No photo found yet (own website and image search run after this page is viewed)
Person

Christoph Lengauer

Executive Officer · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

KK
No photo found yet (own website and image search run after this page is viewed)
Person

Kyle Kuvalanka

Executive Officer · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

OH
No photo found yet (own website and image search run after this page is viewed)
Person

Owen Hughes

Director · 2 shared filings (1 issuer) · also on 4 other issuers

Owen Hughes is on 5 issuers in total — a repeat sponsor. Their page lists every one.

AD
No photo found yet (own website and image search run after this page is viewed)
Person

Abbie C. Celniker, Ph.D.

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

RR
No photo found yet (own website and image search run after this page is viewed)
Person

Rene Russo

Executive Officer, Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Thilo Schroeder

Director · 2 shared filings (1 issuer) · also on 5 other issuers

Thilo Schroeder is on 6 issuers in total — a repeat sponsor. Their page lists every one.

BG
No photo found yet (own website and image search run after this page is viewed)
Person

Barry J. Gertz

Director · 2 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

DC
No photo found yet (own website and image search run after this page is viewed)
Person

Daniel Curran

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Rachel Humphrey

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

TC
No photo found yet (own website and image search run after this page is viewed)
Person

Timothy Clackson

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

PC
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Clancy

Director · 2 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

RI
No photo found yet (own website and image search run after this page is viewed)
Person

Ramy Ibrahim

Director · 2 shared filings (2 issuers)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

DT
No photo found yet (own website and image search run after this page is viewed)
Person

Denice Torres

Director · 2 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

WS
No photo found yet (own website and image search run after this page is viewed)
Person

William R. Sellers

Director · 2 shared filings (2 issuers)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

MR
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Ross

Director · 2 shared filings (1 issuer) · also on 29 other issuers

Michael Ross is on 30 issuers in total — a repeat sponsor. Their page lists every one.

CB
No photo found yet (own website and image search run after this page is viewed)
Person

Christine Bellon

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

JD
No photo found yet (own website and image search run after this page is viewed)
Person

Jay S. Duker

Director · 2 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

LD
No photo found yet (own website and image search run after this page is viewed)
Person

Leslie Dan

Director · 2 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

SH
No photo found yet (own website and image search run after this page is viewed)
Person

Stephen A. Hurly

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

JF
No photo found yet (own website and image search run after this page is viewed)
Person

Joseph Farmer

Executive Officer · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Daniel Lynch. Their page shows their other deals.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

Joshua Resnick

Director · 1 shared filing (1 issuer) · also on 12 other issuers

Joshua Resnick is on 13 issuers in total — a repeat sponsor. Their page lists every one.

The team behind the deals

B
Sponsor group

Bluebird

2 issuers · 6 filings · $245M reported sold · 2010–2022

One team, 2 deal companies. Daniel Lynch is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Daniel Lynch.

TR
Sponsor group

Third Rock

7 issuers · 15 filings · $2.62B reported sold · 2010–2026

One team, 7 deal companies. Daniel Lynch is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Daniel Lynch.

Same business address

30 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 12 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Daniel Lynch by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 12 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Daniel Lynch is listed on: none on file. No website or social profile named in Cardurion Pharmaceuticals, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #94,864 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Burlington, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Massachusetts MassCourts ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Massachusetts Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Daniel Lynch appears on a new Form D, or when a court case or SEC action is matched to them. See plans →